Zimbabwe Reports Stable ARV Supply Despite U.S. Aid Cuts.
Zimbabwe has sufficient antiretroviral drugs for its 1.2 million HIV patients, the National AIDS Council announced this week. The statement addresses public concerns after recent U.S. funding changes threatened treatment programs.
The United States froze support through USAID as part of broader cuts to the President's Emergency Plan for AIDS Relief. PEPFAR stands as Zimbabwe's largest HIV response funder, pledging US$210 million for 2024 and US$200 million for late 2024 through September 2025.
"The nation has enough ARVs in stock," NAC chief executive Bernard Madzima told The Sunday Mail. "Anyone needing medication should visit their regular facility. Services remain available."
Zimbabwe has reduced new HIV infections by 50 percent over ten years through widespread ARV distribution. The country made history as Africa's first to approve CAB-LA, a long-acting injectable HIV prevention drug.
The AIDS levy, which takes 3 percent from corporate profits and personal income, helps fund HIV programs. Yet Madzima noted these local currency collections face limits in purchasing international supplies.
"The AIDS levy represents a finite resource," he said. "It cannot cover all potential health sector gaps," NAC stressed the need for continued resource mobilization to maintain HIV prevention efforts across the country.
Zimbabwe has sufficient antiretroviral drugs for its 1.2 million HIV patients, the National AIDS Council announced this week. The statement addresses public concerns after recent U.S. funding changes threatened treatment programs.
The United States froze support through USAID as part of broader cuts to the President's Emergency Plan for AIDS Relief. PEPFAR stands as Zimbabwe's largest HIV response funder, pledging US$210 million for 2024 and US$200 million for late 2024 through September 2025.
"The nation has enough ARVs in stock," NAC chief executive Bernard Madzima told The Sunday Mail. "Anyone needing medication should visit their regular facility. Services remain available."
Zimbabwe has reduced new HIV infections by 50 percent over ten years through widespread ARV distribution. The country made history as Africa's first to approve CAB-LA, a long-acting injectable HIV prevention drug.
The AIDS levy, which takes 3 percent from corporate profits and personal income, helps fund HIV programs. Yet Madzima noted these local currency collections face limits in purchasing international supplies.
"The AIDS levy represents a finite resource," he said. "It cannot cover all potential health sector gaps," NAC stressed the need for continued resource mobilization to maintain HIV prevention efforts across the country.
